Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free BFRIW Stock Alerts

Biofrontera (BFRIW) Competitors

Biofrontera logo
$0.03 0.00 (0.00%)
As of 08/26/2026 02:16 PM Eastern
Compare

BFRIW vs. SXTPW, CALA, CINGW, CMRAW, and CDTTW

Should you buy Biofrontera stock or one of its competitors? Biofrontera's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Calithera Biosciences (CALA), Cingulate (CINGW), Comera Life Sciences (CMRAW), and Conduit Pharmaceuticals (CDTTW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biofrontera compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
Biofrontera$46.18MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 1 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Biofrontera's score of 1.87 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Biofrontera Very Positive

Summary

60 Degrees Pharmaceuticals and Biofrontera tied by winning 1 of the 2 factors compared between the two stocks.

How does Biofrontera compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, Calithera Biosciences and Calithera Biosciences both had 1 articles in the media. Biofrontera's average media sentiment score of 1.87 beat Calithera Biosciences' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Calithera Biosciences Neutral
Biofrontera Very Positive

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Biofrontera N/A N/A N/A

Biofrontera has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Biofrontera$46.18MN/AN/AN/AN/A

Summary

Biofrontera beats Calithera Biosciences on 2 of the 2 factors compared between the two stocks.

How does Biofrontera compare to Cingulate?

Biofrontera (NASDAQ:BFRIW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Cingulate N/A N/A N/A

In the previous week, Cingulate had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat Cingulate's score of 0.44 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
Cingulate Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Summary

Biofrontera beats Cingulate on 2 of the 3 factors compared between the two stocks.

How does Biofrontera compare to Comera Life Sciences?

Biofrontera (NASDAQ:BFRIW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, Biofrontera had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Comera Life Sciences. Biofrontera's average media sentiment score of 1.87 beat Comera Life Sciences' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
Comera Life Sciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

Summary

Biofrontera beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

How does Biofrontera compare to Conduit Pharmaceuticals?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Conduit Pharmaceuticals and Conduit Pharmaceuticals both had 1 articles in the media. Conduit Pharmaceuticals' average media sentiment score of 1.87 equaled Biofrontera'saverage media sentiment score.

Company Overall Sentiment
Conduit Pharmaceuticals Very Positive
Biofrontera Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
Biofrontera$46.18MN/AN/AN/AN/A

Summary

Biofrontera beats Conduit Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Sign up to receive the latest news and ratings for BFRIW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BFRIW vs. The Competition

Export
MetricBiofronteraPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.15B$7.20B$12.94B
Dividend YieldN/A2.61%2.54%11.02%
P/E RatioN/A775.59271.3124.27
Price / SalesN/A788.76645.3692.25
Price / CashN/A96.4679.8953.65
Price / BookN/A12.0713.016.26
Net IncomeN/A$2.80B$3.46B$348.07M
7 Day PerformanceN/A2.13%1.95%1.40%
1 Month PerformanceN/A6.01%8.17%4.59%
1 Year PerformanceN/A7.43%26.28%17.05%

Biofrontera Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BFRIW
Biofrontera
N/A$0.03
flat		N/A-79.5%$0.00$46.18MN/A70
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
flat		N/AN/A$0.00$1.00MN/A2
CALA
Calithera Biosciences
N/AN/AN/AN/A$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
+1.4%		N/A-77.2%$0.00N/AN/A20
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BFRIW) was last updated on 8/27/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel